Cytokines and Chemokines in Breast Cancer Progression: Immunological Insights and Therapeutic Targets

Abstract

Breast cancer remains one of the most prevalent malignancies worldwide, characterized by complex interactions between tumor cells and the immune system. Increasing evidence underscores the pivotal role of cytokines and chemokines in orchestrating tumor initiation, progression, immune evasion, and metastasis. These soluble mediators function as key regulators of inflammation, cellular communication, and immune cell recruitment within the tumor microenvironment. Pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) promote tumor proliferation and survival, whereas immunosuppressive cytokines like transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10) facilitate immune escape. Chemokines, including CXCL12, CCL2, and CCL5, contribute to metastatic dissemination by directing tumor cell migration and shaping pre-metastatic niches. The dynamic interplay between cytokines, chemokines, and immune cells such as regulatory T cells and myeloid-derived suppressor cells further complicates therapeutic interventions. Recent advances in targeted therapies, including cytokine inhibitors and chemokine receptor antagonists, have opened new avenues for precision oncology. However, challenges such as signaling redundancy, systemic toxicity, and tumor heterogeneity limit clinical success. This review comprehensively examines the biological roles, signaling mechanisms, and therapeutic implications of cytokines and chemokines in breast cancer, highlighting emerging strategies to improve treatment outcomes.